文献速递运动医学关节外科

组织工程二头肌自体肌腱补片促进兔冈下肌腱缺损模型中巨大肩袖缺损修复

Tissue-engineered Bicipital Autologous Tendon Patch Enhances Massive Rotator Cuff Defect Repair in a Rabbit Infraspinatus Tendon Defect Model.
PubMed 文献 · Clin Orthop Relat Res · 2024-09-17

该研究先在体外评估纤维蛋白胶的生物相容性与胶原合成能力,再用新西兰白兔冈下肌腱全层缺损模型,比较组织工程二头肌自体肌腱补片(补片组)与未处理(对照组)及纤维蛋白胶(凝胶组)的修复效果。结果显示补片组组织学评分优于凝胶组和对照组,新生胶原纤维直径大于对照组,RNA测序提示补片通过调节免疫反应、促进胶原纤维组织化和缓解血管收缩促进肌腱再生。

要点

  • 体外实验显示纤维蛋白胶增强肌腱干/祖细胞胶原合成能力(0.38±0.02 vs 0.27±0.02,p<0.001)。
  • 培养14天时组织工程二头肌腱补片细胞生长面积(78.13%±3.68%)较11天、7天、1天显著增加。
  • 移植3个月后补片组组织学评分(3.83±2.01)优于凝胶组(10.67±0.58)和对照组(10.75±0.66)。

核心结论

  • 该动物研究证明组织工程二头肌自体肌腱补片有效调节免疫反应和胶原纤维组织化,从而促进肌腱再生。

研究设计与样本

  • 体外实验评估纤维蛋白胶中肌腱干/祖细胞的存活、增殖和胶原合成能力。
  • 体内动物研究使用8至12周龄新西兰白兔,每只动物左肩手术,雌雄数量相等。
  • 对照组12只兔,凝胶组和补片组各15只兔;1个月和3个月时间点每组各6只兔,2个月时间点凝胶组和补片组各3只兔。
  • 通过冈下肌腱缺损模型,比较组织工程二头肌自体肌腱补片(补片组)与未处理(对照组)及纤维蛋白胶(凝胶组)的修复效果。

主要发现

  • 体外实验显示纤维蛋白胶增强肌腱干/祖细胞胶原合成能力(0.38±0.02)优于单纯标准细胞培养(0.27±0.02,均数差0.11[95%CI 0.07至0.14];p<0.001)。
  • 培养14天时组织工程二头肌腱补片细胞生长面积(78.13%±3.68%)较11天(13.05%±8.78%,均数差-65.08%[95%CI -77.99%至-52.15%];p<0.001)、7天(2.67%±2.62%,均数差-75.46%[95%CI -88.37%至-62.53%];p<0.001)和1天(0.33%±0.30%,均数差-77.80%[95%CI -90.71%至-64.87%];p<0.001)显著增加。
  • 移植3个月后补片组组织学评分(3.83±2.01)优于凝胶组(10.67±0.58,均数差6.84[95%CI 3.67至10.00];p=0.001)和对照组(10.75±0.66,均数差6.92[95%CI 3.75至10.08];p=0.001)。
  • 补片组新生胶原纤维排列规则且直径(77.52±44.41 nm)大于对照组(53.34±6.64 nm,均数差24.18[95%CI 22.24至26.11];p<0.001)。
  • RNA测序分析显示组织工程二头肌自体肌腱补片通过调节免疫反应、促进胶原纤维组织化和缓解血管收缩促进肌腱再生。

关键数值与推荐

  • 体外胶原合成能力:纤维蛋白胶组0.38±0.02 vs 标准细胞培养组0.27±0.02,均数差0.11(95%CI 0.07至0.14),p<0.001。
  • 细胞生长面积:培养14天78.13%±3.68% vs 11天13.05%±8.78%,均数差-65.08%(95%CI -77.99%至-52.15%),p<0.001。
  • 组织学评分:补片组3.83±2.01 vs 凝胶组10.67±0.58,均数差6.84(95%CI 3.67至10.00),p=0.001。
  • 组织学评分:补片组3.83±2.01 vs 对照组10.75±0.66,均数差6.92(95%CI 3.75至10.08),p=0.001。
  • 胶原纤维直径:补片组77.52±44.41 nm vs 对照组53.34±6.64 nm,均数差24.18(95%CI 22.24至26.11),p<0.001。

临床怎么用

  • 组织工程二头肌自体肌腱补片是肌腱再生的有前景策略,在临床肩袖手术中修复巨大肩袖缺损具有潜力。
  • 后续研究可聚焦于使用组织工程二头肌自体肌腱补片的大动物实验,以探索其临床转化的可行性。

局限性

  • 作者指出后续研究可聚焦于使用组织工程二头肌自体肌腱补片的大动物实验,以探索其临床转化的可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Massive rotator cuff defects represent an important source of shoulder pain and functional debilitation, substantially diminishing patients' quality of life. The primary treatment of massive rotator cuff defects includes complete or partial repair and patch augmentation. However, because of the tendon's limited regenerative ability, the tendon retear risk after rotator cuff defect repair is still high. Thus, a new therapy is needed to promote tendon regeneration for repair of massive rotator cuff defects. QUESTIONS/PURPOSES: Using an in vitro analysis, we first asked: (1) What is the biocompatibility and collagen synthesis ability of fibrin glue, and what is the cell growth of tissue-engineered bicipital tendon patches, which is comprised of fibrin glue and biceps tendon tissue particles? Then, using an in vivo animal model of full-thickness defects in the infraspinatus tendon in New Zealand White rabbits, we asked: (2) What is the potential of the tissue-engineered bicipital autologous tendon patch to promote tendon regeneration? METHODS: In vitro experiments were conducted to assess the survival, proliferation, and collagen synthesis ability of tendon stem/progenitor cells cultured in fibrin glue. This was achieved through an assay of live/dead cell viability, cell counting kit-8 (CCK-8) assay, and Sirius red staining, respectively. The in vivo animal study was conducted using 8- to 12-week-old New Zealand White rabbits. The left shoulder of each animal was operated on, with equal numbers of males and females. There were 12 rabbits in the control group and 15 rabbits each in the gel and patch groups. Six rabbits were allocated to each of the three groups at the 1- and 3-month time points and three rabbits each were in the gel and patch groups at 2-month time point. Through an infraspinatus tendon defect model, the effectiveness of tissue-engineered bicipital autologous tendon patches (patch group) in tendon repair was assessed compared with untreated (control group) and fibrin glue (gel group) treatments in vivo. This assessment included histological evaluation of repaired tissue morphology, transmission electron microscopy (TEM) evaluation of regenerated collagen fibrils, and RNA sequencing to explore the potential mechanisms of tissue-engineered bicipital autologous tendon patches in tendon regeneration. RESULTS: In vitro experiments demonstrated that fibrin glue enhanced the collagen synthesis ability of tendon stem/progenitor cells (0.38 ± 0.02) compared with standard cell culture alone (0.27 ± 0.02, mean difference 0.11 [95% CI 0.07 to 0.14]; p < 0.001). With prolonged cultivation, the cell growth area of tissue-engineered bicipital tendon patches showed a notable increase after culturing for 14 days (78.13% ± 3.68%) compared with 11 days (13.05% ± 8.78%, mean difference -65.08% [95% CI -77.99% to -52.15%]; p001), 7 days (2.67% ± 2.62%, mean difference -75.46% [95% CI -88.37% to -62.53%]; p001), and 1 day (0.33% ± 0.30%, mean difference -77.80% [95% CI -90.71% to -64.87%]; p<0.001). At 3 months after transplantation, in vivo experiments revealed that compared with the control and gel groups, the patch group displayed improved repair outcomes. This was evidenced by better histological scores in the patch group (3.83 ± 2.01) compared with the gel group (10.67 ± 0.58, mean difference 6.84 [95% CI 3.67 to 10.00]; p = 0.001) and control group (10.75 ± 0.66, mean difference 6.92 [95% CI 3.75 to 10.08]; p = 0.001), and by regular alignment and larger diameters of newly formed collagen fibrils in the patch group (77.52 ± 44.41 nm) compared with the control group (53.34 ± 6.64 nm, mean difference 24.18 [95% CI 22.24 to 26.11]; p < 0.001). RNA sequencing analysis revealed that a tissue-engineered bicipital autologous tendon patch facilitated tendon regeneration by modulating the immune response, promoting collagen fibril organization, and alleviating vasoconstriction. CONCLUSION: This animal study demonstrates that the tissue-engineered bicipital autologous tendon patch effectively modulates an immune response and collagen fibril organization, leading to the promotion of tendon regeneration. CLINICAL RELEVANCE: The tissue-engineered bicipital autologous tendon patch represents a promising strategy for tendon regeneration, offering potential in the repair of massive rotator cuff defects during clinical rotator cuff surgery. Subsequent research could focus on large animal experiments using a tissue-engineered bicipital autologous tendon patch to explore their feasibility for clinical translation.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Liao Y, Liu H, Huang J, et al. Tissue-engineered Bicipital Autologous Tendon Patch Enhances Massive Rotator Cuff Defect Repair in a Rabbit Infraspinatus Tendon Defect Model. Clin Orthop Relat Res. 2024. PMID: 39467146. doi:10.1097/CORR.0000000000003218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。